Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02968849

Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa (HVTN702)

A Pivotal Phase 2b/3 Multisite, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in Preventing HIV-1 Infection in Adults in South Africa

Sponsor: Bill and Melinda Gates Foundation

Conditions HIV Infections

Interventions ALVAC-HIV (vCP2438) Bivalent Subtype C gp120/MF59 Placebo

Updated 19 times since 2017 Last updated: Jul 10, 2024 Started: Oct 26, 2016 Primary completion: Nov 16, 2021 Completion: Nov 16, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on HIV Infections, this trial is completed. The trial is conducted by Bill and Melinda Gates Foundation and has accumulated 19 data snapshots since 2016. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

19 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Aug 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Aug 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Apr 2024 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2024 — Apr 2024 [monthly]

Completed PHASE2_PHASE3

▶ Show 14 earlier versions

Nov 2023 — Jan 2024 [monthly]

Completed PHASE2_PHASE3
May 2023 — Nov 2023 [monthly]

Completed PHASE2_PHASE3
Mar 2023 — May 2023 [monthly]

Completed PHASE2_PHASE3
Jun 2022 — Mar 2023 [monthly]

Completed PHASE2_PHASE3

Status: Active Not Recruiting → Completed
May 2021 — Jun 2022 [monthly]

Active Not Recruiting PHASE2_PHASE3
Jan 2021 — May 2021 [monthly]

Active Not Recruiting PHASE2_PHASE3
Sep 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2_PHASE3
Mar 2020 — Sep 2020 [monthly]

Active Not Recruiting PHASE2_PHASE3
Sep 2019 — Mar 2020 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Recruiting → Active Not Recruiting
Jul 2019 — Sep 2019 [monthly]

Recruiting PHASE2_PHASE3
Jun 2018 — Jul 2019 [monthly]

Recruiting PHASE2_PHASE3
Dec 2017 — Jun 2018 [monthly]

Recruiting PHASE2_PHASE3
Feb 2017 — Dec 2017 [monthly]

Recruiting PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bill and Melinda Gates Foundation
GlaxoSmithKline
National Institute of Allergy and Infectious Diseases (NIAID)
Sanofi

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cape Town, South Africa , Durban, South Africa , Isipingo, South Africa , Johannesburg, South Africa , Klerksdorp, South Africa , Ladysmith, South Africa , Mthatha, South Africa , Pretoria, South Africa , Rustenburg, South Africa , Soshanguve, South Africa and 1 more location